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Identity 
Other names: BP-8; CSDA2; CSDB; DBPB; MDR-
NF1; MGC104858; MGC110976; MGC117250; 
NSEP-1; NSEP1; YB-1; YB1 
HGNC (Hugo): YBX1 
Location: 1p34.2 
Local order: The human YBX1 gene maps on 1p34 
between the PPIH and the LOC100287607 loci. 
DNA/RNA 
Description 
The human YBX1 gene consists of 8 exons and 7 
introns spanning a 19.2-kb genomic region. Intron 
number 1 is phase 1 (between 1st and 2nd base of 
codon). Introns number 2 and 6 are phase 2 (between 
2nd and 3rd base of codon). Introns number 3, 4, 5 are 
phase 0 (between codons). According to the SNP 
source (dbSNP NCBI), non-synonymous 
polymorphism has been reported for the codons 30 
(rs11558135), 237 (rs3887881), 251 (rs55676223), and 
261 (rs3887879). The YBX1 promoter region contains 
no typical TATA or CCAAT box, but has multiple E-
boxes located between -1855 and -422 nucleotides 
(relative to the start of exon 1) and several GT and GC 
boxes. The gene also contains a large and highly 
conserved CpG island at the immediate 5' promoter 
region which extends to the first exon encoding 5' UTR 
of YBX1 mRNA. The region between nucleotides -119 
to +127 was shown to be essential for transcriptional 
activity in the reporter assays (Makino et al., 1996). 
YBX1 is constitutively expressed in multiple human 
tissues and its expression can be further induced by the 
E-box-binding transcription factors such as c-myc 
(Uramoto et al., 2002), Twist (Shiota et al., 2008) and 
Math2 (Ohashi et al., 2009). 
Transcription 
The main processed mRNA is 1514 bp. It encompasses 
exons 1-8. The 70-amino acid cold-shock domain 
(CSD) is encoded separately by exons 2-5. Four 
additional splice variants in human were predicted 
(Ensembl), two of which (YBX1-004 and YBX1-201) 
preserve exons 2 and 3 coding for core elements of the 
CSD, the RNP1 and RNP2 motifs, respectively. An 
alternative transcript for ctYB-1, the YBX1 
homologous gene in C. tentans, has been reported 
(Nashchekin et al., 2007). 
 
 
Genomic organization of YBX1. Box = exon (blue = 5'UTR, yellow = CDS, light red = 3'UTR). Line = intron. 




















protein 1 pseudogene 







Y box binding protein 
1 pseudogene 1 








Y box binding protein 
1 pseudogene 2 
YBX1P2 646531 7q22.3 


























The YBX1 gene encodes the Y-box protein 1 (YB-1) 
which consists of 324 amino acid residues and has te 
isoelectric point 10.3. Theoretical MW is 35924, 
however YB-1 is known to migrate as a ~45-50 kDa 
protein in SDS-polyacrylamide gels due to its 
anomalous electrophoretic mobility. YB-1 belongs to 
the family of multifunctional DNA/RNA binding 
proteins that are highly conserved throughout evolution 
and found in eukaryotes, prokaryotes and archaea. The 
most conserved region in YB-1 is the 80 amino acid 
CSD which exhibits >40% identity and >60% 
similarity to the major E. coli cold shock protein CspA 
(Matsumoto and Wolffe, 1998; Sommerville, 1999). 
The CSD possesses RNP1 and RNP2-like consensus 
motifs and is represented by a five-stranded beta-barrel 
structure which creates a surface rich in aromatic nd
basic amino acids that may act as a large nucleic acid-
binding site (Wolffe et al., 1992; Wolffe, 1994). The 
CSD has a preference for binding single-stranded 
pyrimidine-rich sequences. The N-terminal AP domain 
of YB-1 is similar to that found in several other 
transcription factors and may thus be important for its 
transcriptional activity. This region is also essential for 
interaction with p53 and modulation of p53-mediated 
transcription (Okamoto et al., 2000), and for 
association with actin microfilaments and mRNA 
compartmentalization (Ruzanov et al., 1999).  
The C-terminal region of YB-1 is responsible for 
sequence-nonspecific binding to DNA and RNA and 
mediation of protein-protein interactions (Wolffe, 
1994; Sommerville and Ladomery, 1996). An inverted 
CCAAT-box found in HLA class II gene promoters, a 
so-called Y-box, was originally determined as the YB-1 
binding motif (Didier et al., 1988). Later studies have 
concluded that YB-1 rather recognizes the DNA 
structure than a defined nucleotide sequence, making 
prediction of its target genes not feasible with 
conventional in silico analyses (Swamynathan et al., 
1998). YB-1 is also capable of unwinding DNA and 
RNA duplexes, especially those containing 
mismatches, thereby promoting strand exchange and 
formation of perfectly matched duplex structures 
(Skabkin et al., 2001; Gaudreault et al., 2004). 
Expression 
According to Human Protein Atlas, YB-1 is variably 
expressed in most normal human tissues. Its expression 
is elevated in multiple cancer types (Kohno et al.,
2003). 
Localisation 
Mostly cytosolic. Shuttles between cytoplasm and 
nucleus. Localized in cytoplasmic stress granules and 
processing bodies containing untranslated mRNAs 
(Kedersha and Anderson, 2007). Nuclear translocation 
is induced in response to various stresses, including 
adenoviral infection (Holm et al., 2002), hyperthermia 
(Stein et al., 2001), DNA damage (Kohno et al., 2003) 
and activation of 
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Structural and functional organization of YB-1. YB-1 is composed by three domains: N-terminal Ala/Pro rich (AP) domain, cold shock 
domain (CSD) and the C-terminal domain (CTD) containing clusters of positively and negatively charged amino acids. Indicated are 
some known molecular partners of YB-1 and sites of their interactions (from Sorokin et al., 2005). The arrow indicates proteasomal 
cleavage sites. 
 
PI3K-Akt signaling (Sutherland et al., 2005). 
Function 
The diverse biological functions of YB-1 appear to 
arise from its broad nucleic acid binding properties. 
YB-1 has been implicated in pre-mRNA splicing, 
transcriptional regulation, mRNA translation and 
stability as well as in chromatin remodelling, DNA 
repair and environmental stress responses (Kohno et 
al., 2003; Matsumoto and Bay, 2005). 
Splicing. YB-1 regulates splice site selection via direct 
binding to splicing recognition motifs in pre-mRNA, 
including A/C-rich exon enhancers (Stickeler et al., 
2001) or via interaction with splicing factors from the 
SR family (Li et al., 2003; Raffetseder et al., 2003). 
Transcription. YB-1 is capable of binding to 
promoters of many genes, many of which lack the Y-
box, and either activates or represses transcription. 
Among the genes activated by YB-1 are thymidine 
kinase, proliferating cell nuclear antigen (PCNA), 
cyclin A and cyclin B1, DNA topoisomerase II alpha, 
gelatinase A, matrix metalloproteinase 2, multidrug 
resistance 1 (MDR1), EGFR and protein tyrosine 
phosphatase 1B. Genes that are transcriptionally 
repressed by YB-1 include MHC class II, collagen 
alpha1, granulocyte-macrophage colony-stimulating 
factor (GM-CSF), etc (reviewed in Ladomery and 
Sommerville, 1995; Kohno et al., 2003; Kuwano et al., 
2003). Overall, YB-1 is considered as an important 
regulator of growth- and stress-associated genes. 
mRNA translation and stability. YB-1 (p50) is 
known as a major structural component of messenger 
ribonucleoprotein particles (mRNPs) which exerts 
positive or negative effects on translation, depending 
on the amount bound to mRNA (Evdokimova and 
Ovchinnikov, 1999). YB-1 regulates translational 
activity of many growth- and differentiation-associated 
mRNAs, including Snail1, and selectively protects 
capped mRNAs against degradation (Evdokimova et 
al., 2001; Evdokimova et al., 2006; Evdokimova et al., 
2009). YB-1 appears to play a role in stabilization of 
short-lived mRNAs, including IL-2 (Chen et al., 2000), 
GM-CSF (Capowski et al., 2001) and VEGF (Coles et 
al., 2004). 
DNA repair and stress response. YB-1 is involved in 
base excision and mismatch repair pathways via 
interaction with multiple DNA repair proteins including 
glycosylase NEIL2, DNA polymerase beta and delta, 
DNA ligase III, APE1, MSH2, Ku80, WRN, 
endonuclease III, etc (Marenstein et al., 2001; 
Gaudreault et al., 2004; Das et al., 2007). YB-1 also 
directly binds and promotes separation of DNA strands 
that contain mismatches or are modified by cisplatin 
(Ise et al., 1999; Skabkin et al., 2001; Gaudreault et al., 
2004). Various stresses, including DNA damage, 
adenovirus infection and hyperthermia, induce nuclear 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(7)  601 
translocation of YB-1 (Ohga et al., 1996; Kohno et al., 
2003) and its proteasomal cleavage (Sorokin et al., 
2005). Accumulation of the full-length and/or truncated 
YB-1 proteins in the nucleus is associated with 
increased survival and multidrug resistance (Kohno et 
al., 2003; Sorokin et al., 2005). YB-1 knock-out in 
mice is lethal (Lu et al., 2005; Lu et al., 2006). 
Fibroblasts derived from YB-1(-/-) embryos exhibit a 
reduced ability to respond to oxidative, genotoxic and 
oncogene-induced stresses, further implicating YB-1 in 
stress responses and embryonic development. 
Tumorigenesis. YB-1 is frequently overexpressed in 
multiple human cancers (reviewed in Kohno et al., 
2003; Kuwano et al., 2003). In many cases, YB-1 
levels are elevated in the nucleus, positively correlating 
with multiple drug resistance and poor patient outcme 
(Bargou et al., 1997; Janz et al., 2002). Ectopic 
expression of YB-1 in breast cancer cells and mouse 
models stimulated tumor growth (Bergmann et al., 
2005; Sutherland et al., 2005). Yet, the role of YB-1 in 
tumorigenesis is controversial. YB-1 overexpression 
blocked oncogenic transformation caused by PI3K or 
Akt (Bader et al., 2003). These apparently 
contradictory results were proposed to be due to 
differential localization of YB-1; its interference with 
oncogenic transformation is associated with cytosolic 
localization and a consequent function in translational 
control (Bader and Vogt, 2004; Bader and Vogt, 2005). 
Homology 
YB-1 is highly homologous to human DbpA (12p13; 
expressed predominantly in heart and muscle) and 
DbpC/contrin (17p11; expressed exclusively in germ 
cells). They share greater than 90% identity within t e 
CSD and a high degree of similarity in the N- and C-
terminal domains, including C-terminal clusters of 
basic and acidic amino acids. Mouse orthologues are 
YB-1 (encoded by Ybx1; 99% overall aminoacid 
identity with human YB-1), MSY2 (Ybx2; ~93% 








Elevated expression and nuclear localization of YB-1 is 
associated with increased proliferation, multidrug 
resistance and tumor aggressiveness across all tumor 
subtypes. Nuclear localization positively correlates 
with increased expression of MDR1/P-gp and 
HER2/ErbB2 (Bargou et al., 1997; Saji et al., 2003; 
Fujii et al., 2008; Habibi et al., 2008). Enforced YB-1 
expression in mammary glands of transgenic mice 
induced chromosomal instability and tumorigenesis 
(Bergmann et al., 2005). YB-1 effects on tumorigenesis 
are likely dependent on cellular signaling. It blocks 
oncogenic transformation induced by Akt or PI3K but
not by Src, Jun or Qin oncoproteins (Bader et al., 
2003), and decreases proliferation of tumor cells with 
activated MAPK-Ras signaling, while inducing their 
metastatic ability (Evdokimova et al., 2009). 
Prognosis 
Nuclear YB-1 is considered as a marker of poor clinical 
outcome. Patients with high YB-1 levels are likely to 
benefit from dose-intensified chemotherapy regimens 
(Gluz et al., 2009). 
Prostate cancer 
Note 
YB-1 is upregulated during prostate cancer tumor 
progression and is reported to increase P-glycoprotein 
activity (Giménez-Bonafé et al., 2004). 
Lung cancer 
Note 
Nuclear YB-1 is associated with poor survival and 
expression of HER2/ErbB2 and HER3/ErbB3 in non-
small cell lung cancer (Kashihara et al., 2009). 
Prognosis 
Patients with nuclear YB-1 expression and p53 
mutations appear to have the worst prognosis (median 
survival 3 months), while best outcome was found in 
patients with no nuclear YB-1 and wild-type p53 
(Gessner et al., 2004). 
Colon cancer 
Note 
YB-1 expression levels are elevated in colorectal 
carcinoma and positively correlate with DNA 
topoisomerase II alpha and PCNA expression but not 
with P-gp (Shibao et al., 1999). In colon cancer cells, 
YB-1 accumulates in the nuclei in response to 
vinblastin and is associated with development of 
vinblastin resistance and elevated expression of P-gp 
(Vaiman et al., 2007). 
Ovarian cancer 
Note 
YB-1 levels are elevated in the nuclei of cisplatin-
resistant cancer cell lines and cancer patients, 
indicating that nuclear YB-1 may be associated with 
acquired cisplatin resistance in ovarian cancers (Yahata 
et al., 2002). 
Prognosis 
Co-expression of YB-1 and P-gp is indicative of 




Large B-cell lymphoma, multiple myeloma. 
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Nuclear expression of YB-1 is associated with P-gp 
expression and poor response to chemotherapy in large
B-cell lymphoma (Xu et al., 2009). YB-1 is strongly 
expressed in normal plasma cell precursor blasts as 
well as in a multiple myeloma tumor specimens and 
cell lines but not in normal bone marrow or plasma 
cells. Its expression is associated with an immature 
morphology, a highly proliferative phenotype and 
doxorubicin resistance, indicating its involvement i  
drug resistance and disease progression in multiple 
myeloma (Chatterjee et al., 2008). 
Bone and soft tissue tumors 
Disease 
Rhabdomyosarcoma, synovial sarcoma and 
osteosarcoma. 
Nuclear expression of YB-1 protein positively 
correlates with P-gp expression and a higher 
proliferative index in embryonal (ERMS) but not in 
alveolar rhabdomyosarcoma (ARMS) (Oda et al., 
2008), synovial sarcoma (Oda et al., 2003) and 
osteosarcoma (Oda et al., 1998). 
Melanoma 
Note 
YB-1 expression is increased in melanoma cells 
compared to benign melanocytes, and nuclear YB-1 is 
found in invasive and metastatic melanoma cells. YB-1 
expression is associated with increased proliferation, 
tumor invasion and chemoresistance (Schittek et al., 
2007). 
Nervous system tumors 
Disease 
Glioblastoma, neuroblastoma. 
YB-1 levels are elevated in pediatric glioblastoma 
(Faury et al., 2007) and neuroblastoma (Wachowiak et 
al., 2010). 
Prognosis 
In neuroblastoma, no correlation of YB-1 expression 
with survival, risk factors or stage of the disease was 
found. 
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